Estonian, Finnish Companies Cooperate to Find a Cure for Ebola ({{commentsTotal}})


Estonian biotechnology group Icosagen, in cooperation with FIT Biotech from Finland, are planning on programs to develop a vaccine and a cure for Ebola.

Mart Ustav, the founder and CEO of Icosagen and a professor of biomedicine technology at the University of Tartu, told Eesti Päevaleht that work on the vaccine will start presently and the first clinical trials should be under way in 2016, but it is too early to say when the new product will arrive in the market.

The QMCF Technology that Icosagen developed and holds a patent for, has been licensed to a number of large pharmaceutical and biotechology companies. The QMCF system can be used for the production of proteins, antibodies and virus-like particles for basic research and pharmaceutical development.

"As our technology could be used to develop a vaccine for Ebola, we feel we have a duty to participate in the fight against this disease," Ustav said. "I am confident that our collaboration makes a contribution to its prevention and cure."

Also involved in the project in its various stages are the Institute of Technology of the University of Tartu and partners from France and Switzerland.

+{{cc.replyToName}} {{cc.body}}
No comments yet.
Logged in as {{user.alias}}. Log out
Login failed

Register user/reset password

Name needs to be fewer than 32 characters long
Comment needs to be fewer than 600 characters long

Independence Day: Estonia’s way into the future isn’t a race

There is a lack of connection between the Estonian state, and the people who live here. While it expects a lot of the state, Estonian society doesn’t seem ready to contribute, writes Viktor Trasberg.

Lotman: Security academy would be crucial Estonian identity point in Narva

In an opinion piece published by Eesti Päevaleht, Tallinn University professor Mihhail Lotman found it important to overcome the mental barrier separating Ida-Viru County from the rest of Estonia.